FDA approves advanced breast cancer drug

Women with an aggressive form of advanced breast cancer that other treatments have failed to stop gained a new option Tuesday with the approval of a novel drug — but how much benefit it offers is unclear.
The GlaxoSmithKline PLC drug, Tykerb, is to be taken once daily in pill form and is meant for women who have received prior treatment with the intravenous drug Herceptin and older chemotherapy drugs called taxanes and anthracyclines, the company said. The Food and Drug Administration said it approved Tykerb for use in conjunction with the chemotherapy drug Xeloda.
Glaxo said Tykerb would be available in two weeks. It will cost about $2,900 a month, the company said.
http://news.yahoo.com/s/ap/20070313/ap_on_he_me/breast_cancer